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Epidemiology/Population Science
An Analysis of Prospective Risk Factors for Aortic Stiffness
in Men
20-Year Follow-Up From the Caerphilly Prospective Study
Carmel M. McEniery, Michael Spratt, Margaret Munnery, John Yarnell, Gordon D. Lowe,
Ann Rumley, John Gallacher, Yoav Ben-Shlomo, John R. Cockcroft, Ian B. Wilkinson
Abstract—Arterial stiffness is an important determinant of cardiovascular risk. The precise risk factors for arterial
stiffening remain unclear. We aimed to identify potential risk factors using prospective exposure data from the
Caerphilly Prospective Study. Aortic pulse wave velocity and augmentation index were measured in 825 men and
related to current (2004) and baseline (1979–1988) anthropometric, hemodynamic, and biochemical factors. The mean
age of the men was 74 years, with an average follow-up of 20 years. The only independent baseline predictors of current
velocity were pulse pressure (standardized -coefficient: 0.58), C-reactive protein (0.35), glucose (0.25), and waist
circumference (0.23). The sole baseline predictor of current augmentation index was fibrinogen (0.78). After additional
adjustment for the corresponding current risk factor, pulse wave velocity was best related to cumulative exposure to
C-reactive protein, whereas augmentation index was most strongly related to current levels. Velocity was also more
strongly correlated with baseline levels of triglycerides and smoking but with current waist circumference. The pulse
pressure heart rate product assessed over the whole of 20 years was independently correlated with aortic pulse wave
velocity but not augmentation index. Other than blood pressure, established cardiovascular risk factors have only a
modest effect on aortic stiffness and wave reflection. Inflammation and the level of repetitive cyclic stress are important
predictors of aortic stiffness, whereas wave reflection is predicted by acute inflammation only. Adequate control of pulse
pressure and heart rate, as well as reducing inflammation, may, in the long-term, retard aortic stiffening, although this
remains to be tested directly. (Hypertension. 2010;56:36-43.)
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The large arteries play an important physiological role inbuffering the cyclic changes in pressure resulting from
intermittent ejection of blood. As these vessels stiffen, there
is a reduction in buffering capacity and a concomitant rise in
pulse pressure and fall in shear stress.1 These effects are
thought to promote cardiovascular disease.2 Indeed, aortic
pulse wave velocity (aPWV) is a predictor of future cardio-
vascular risk in a variety of populations,3,4 and this may be
independent of blood pressure (BP).5 As such, it is frequently
considered as the gold-standard measure of arterial stiffness.
The precise mechanisms responsible for arterial stiffening
are incompletely understood but are thought primarily to
involve structural changes within the medium, such as fatigue
fracture of elastin6 and deposition of collagen and calcium.1
Functional changes in smooth muscle tone, mediated, in part,
by endothelial-derived factors, such as NO, may also be
important.7,8 Interestingly, there is considerable variability in
arterial stiffness, suggesting that it is subject to environmental
and genetic influences.9,10 Traditional cardiovascular risk
factors, as well as renal dysfunction, excessive sodium intake,
and the metabolic syndrome, have all been linked to arterial
stiffness.1 However, the majority of these associations stem
from small, cross-sectional studies, which have a number of
limitations, such as inherent bias and reverse causality,
limiting our ability to attribute causality. A recent systematic
review suggested that the impact of established cardiovascu-
lar risk factors, other than BP, on aPWV was very modest.11
Longitudinal studies may provide better evidence of causal-
ity. However, although data concerning longitudinal changes
in pulse pressure, an indirect surrogate of aortic stiffening, are
available,12 only 2 studies on the basis of aPWV measure-
ments in a single French cohort have been published.13,14
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We hypothesized that aPWV would relate to exposure to
traditional cardiovascular risk factors over time but also to the
pulse pressure heart rate product as a measure of the long-
term cyclic stress that the elastic arteries experience. The aim
of the present study was to test this hypothesis in a
population-based longitudinal cohort of men enrolled in the
Caerphilly Prospective Study,15 by relating current aPWV
and augmentation index (AIx) to anthropometric, hemody-
namic, and biochemical data assessed both cross-sectionally
and prospectively over the last 25 years.
Methods
Population
The Caerphilly Prospective Study is a population-based cohort study
of all men (99% white, born in Wales) aged 45 to 59 years residing
in the town of Caerphilly.15 It was set up to investigate risk factors
for cardiovascular disease. The initial examination (phase I) was
between 1979 and 1983 and involved 2512 men. An additional 447
patients were recruited at phase II (July 1984 to June 1988).16 Men
were reseen approximately every 5 years. The last follow-up (phase
V) occurred between 2002 and 2004 and specifically included aPWV
and AIx. Subjects gave written informed consent, and the study had
the approval of the local research ethics committee and adhered to
the Declaration of Helsinki.
Clinical Measures
A detailed medical questionnaire was administered. Height, weight,
and waist circumference were recorded at each visit. Seated brachial
artery BP was measured in duplicate using a Hawksley random 0
sphygmomanometer at phases I through IV and the validated
Omron-705CP at phase V.17
Arterial Hemodynamics
Additional measurements of aPWv and AIx were undertaken at
phase V. AIx, a measure of wave reflection, was determined from
radial waveforms using the validated SphygmoCor device (AtCor
Medical).18–20 Mean arterial pressure (MAP) was calculated from
integration of the radial artery waveform. The same device was used
to measure aPWV from sequentially recorded ECG-gated carotid and
femoral artery waveforms.21 All of the measurements were made in
duplicate by a single operator (M.M.). The reproducibility of
measurements met our previously published criteria.21
Venous Blood Samples
At phases I, II, and V, total cholesterol, low-density lipoprotein
cholesterol, high-density lipoprotein cholesterol, triglycerides, glu-
cose, insulin, and fibrinogen levels were assessed. In phase I,
C-reactive protein (CRP) was measured using an in-house ELISA
method as described previously.22 In phases II and V, CRP was
measured using a high-sensitivity assay (immunonephelometry;
Dade Behring). Phase V undertook a more limited number of blood
assays, so there was not always a phase V equivalent measure for
each of the baseline measures.
Data Analysis
Because of the inclusion of additional subjects at phase II, we used
an average of phase I and II values as baseline measures. To identify
factors underlying current arterial stiffness and wave reflection, we
compared the strength of association between aPWV and AIx with
baseline variables and variables measured at phase V (current).
There was only limited collinearity between our 2 exposure measures
over time, and even waist circumference, which showed stronger
correlation, was not so strong as to distort the SEs.23
For the quoted regression coefficients, the outcome variable is in
its natural units, whereas the exposure variable has been rescaled to
a z score (the mean value of that variable has been subtracted from
the raw value, and the difference has then been divided by an SD,
thereby converting the mean value to 0 and the SD to 1). The
coefficients from our regression therefore indicate the change in
pulse wave velocity for a 1-SD change in the exposure (we have
defined this as the “standardized coefficient”).
aPWV was automatically adjusted for age, MAP, heart rate, and
vasoactive drug use. With AIx, we automatically adjusted for age,
heart rate, height, and vasoactive drug use. Logarithmic transforma-
tions were used for skewed variables. Multivariable linear regression
was used to assess the strength of associations, derive 95% CIs, and
determine significance. The variables entered into the model were
chosen if significantly associated in simple correlation analyses, as
well as those variables known or previously associated with the
dependent variable from published observations.
The heart rate pulse pressure product was calculated for the whole
follow-up period by multiplying heart rate and brachial pulse
pressure recorded at each screening visit (phases I to V) and
integrating across the time interval between visits by using the area
under the curve. The area under the curve is approximated by the
area under the graph of the predictor when linearly interpolated
between the measurement time points, thereby calculating the areas
of a series of trapezoids. This was then repeated while also including
the systolic BP value at each phase.
Results
A total of 1225 men were identified for the main phase V
study, but arterial stiffness measurements were completed in
825 men (67%) because of a delay in starting the measure-
ments (Figure 1). The average duration of follow-up was
202 years. Table 1 provides the baseline (phase I/II) and
current (phase V) demographic, hemodynamic, and biochem-
ical data for the whole cohort, as well as those men with
stiffness measurements. The latter were, at baseline, on
average younger, less likely to smoke, and had a lower waist
circumference, BP, heart rate, triglyceride level, CRP, and
fibrinogen levels but higher creatinine than those who died or
were lost to follow-up. Compared with 20 years ago, body
mass index and waist circumference, pulse and mean pres-
sures, and heart rate had increased, whereas smoking fre-
quency and diastolic pressure had declined in those men with
stiffness measurements. Total and low-density lipoprotein
cholesterol declined, and high-density lipoprotein cholesterol
and CRP levels increased over the 20-year follow-up. Over-
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Figure 1. Schema for the study design. Risk fac-
tors were assessed at baseline and follow-up.
Pulse pressure and heart rate were available at
each of the phases. The aPWV and AIx were only
available at phase V.
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all, 43% of respondents currently had isolated systolic hyper-
tension, 10% had diabetes mellitus, 31% were receiving
aspirin, and 18% were receiving a statin.
Association Between Baseline (Phases I/II)
Variables With PWV and AIx
After adjustment for age, MAP, heart rate, and vasoactive
drug use at phase V, aPWV was positively associated with
baseline systolic BP, MAP, pulse pressure, heart rate, fibrin-
ogen, CRP, triglycerides, waist circumference, and heavy
cigarette smoking (Table 2) and inversely associated with
creatinine. In contrast, AIx only showed associations with
baseline fibrinogen, CRP, and heavy smoking status.
Association Between Current (Phase V) Variables
With PWV and AIx
aPWV was significantly associated with age, MAP, and heart
rate measured at phase V. After adjustment for these variables
and drug usage, aPWV remained significantly associated with
current CRP, creatinine, and waist circumference (Table 2).
Likewise, AIx was associated with age, heart rate, and height
at phase V. After adjustment for these parameters and drug
usage, only current CRP, total cholesterol, and waist circum-
ference remained predictive (Table 2).
Multivariable Analyses of Baseline Variables
Baseline pulse pressure, CRP, glucose, and waist circumfer-
ence were all independently associated with current aPWV
(Table 3 and Figure 2). We chose only to include pulse
pressure rather than both pulse pressure and SBP in the model
because of their collinearity. Similarly, for AIx, only fibrin-
ogen remained a predictor.
Comparison of Baseline and Current Variables
To investigate whether lifetime cumulative exposure or
whether past/current exposure was relatively more important,
we compared the strength of association with baseline and
current values after mutual adjustment (Table 4). These
variables were only moderately correlated across time (0.20
to 0.41), except for waist circumference, which showed a
higher correlation (0.78). This model is algebraically equiv-
alent to modeling the difference in levels between the 2 time
points and conditioning on the later measure.24
For aPWV, both baseline and current CRPs showed strong
positive associations, suggesting that life course accumulative
exposure was the best predictor. For triglycerides, only
baseline exposure remained a predictor, so that, conditional
on the midlife value, later changes in triglycerides add little to
current aPWV. A similar pattern was seen with heavy
Table 1. Subject Characteristics at Baseline and Phase V, for Those With and Without Arterial
Stiffness Measures
Variable Without Measures, Phase I/II
With Stiffness Measures Significance Phase I/II
With and Without
PWVPhase I/II Phase V
No. 2134 825 825
Age, y 584 565 744† 0.001
BMI, kg/m2 26.23.8 26.23.7 27.73.6† 0.7
Waist circumference, cm 94.410.9 93.210.3 100.59.6† 0.02
Smokers, % 61 41 16† 0.001
Peripheral systolic BP, mm Hg 14620 14220 14120 0.003
Peripheral diastolic BP, mm Hg 884 8711 7411† 0.005
Mean pressure, mm Hg 10813 10613 9713† 0.001
Pulse pressure, mm Hg 5715 5515 6716† 0.001
Heart rate, bpm 7011 6610 6411* 0.001
aPWV, m/s 11.52.8
Aortic AIx, % 29.87.8
Total cholesterol, mmol/L 5.81.1 5.81.0 4.81.0† 0.5
Low-density lipoprotein cholesterol,
mmol/L
3.81.1 3.81.0 2.80.9† 0.3
High-density lipoprotein cholesterol,
mmol/L
1.30.4 1.20.3 1.30.3† 0.4
Triglycerides, mmol/L 1.7 (1.1 to 2.3) 1.6 (1.1 to 2.1) 1.5 (1.0 to 1.9)† 0.009
Glucose, mmol/L 5.00.5 5.00.5 0.4
Creatinine, mol/L 97 (89 to 106) 98 (91 to 106) 97 (84 to 108) 0.04
CRP, mg/L 2.3 (1.0 to 4.0) 1.6 (0.8 to 2.3) 2.6 (1.5 to 5.6)† 0.001
Fibrinogen, g/L 3.1 (2.6 to 3.7) 2.8 (2.4 to 3.2) 0.001
Values represent meanSD, or geometric mean and (interquartile range). Differences between phase I values for those with and
without stiffness measures are indicated in the final column.
Significant differences between phase I and V for those with stiffness measures are indicated by *P0.05 and †P0.001.
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smoking, although the baseline value was consistent with
chance. In contrast, current waist circumference was a stron-
ger predictor than baseline waist circumference, although
again this was attenuated and was consistent with chance
variation. Neither of the paired values for triglycerides, waist
circumference, or smoking was significantly associated with
AIx after mutual adjustment, but current CRP showed a
stronger association than baseline CRP with marginal
significance.
Heart Rate Pulse Pressure Product
aPWV was correlated with heart rate brachial pulse pressure
product over the 20-year follow-up (R0.57; P0.001). This
remained significant after adjusting for current age, heart rate,
MAP, and vasoactive drug use. The relationship between
tertiles of average pulse pressure and tertiles of heart rate on
mean aPWV is illustrated in Figure 3. There were significant
linear effects for each variable within each strata (P0.001).
The highest aPWV was observed in individuals in the highest
tertile of pulse pressure and heart rate. There was no evidence
of any interaction between these 2 covariates (P0.84).
There was no relationship between pulse pressure heart rate
product and AIx. We then divided the pulse pressure and
heart rate product into quintiles and used this as a predictor of
aPWV. This showed a significant linear effect (0.60 m/s
[95% CI: 0.38 to 0.82 m/s]; P0.001) per unit quintile
increase. This persisted after adjustment for fibrinogen, CRP,
triglycerides, waist circumference, and smoking status at
baseline (0.53 m/s [95% CI: 0.29 to 0.76 m/s]; P0.001). We
repeated these results using the heart rate SBP product. This
gave very similar results, so that in the simple model, aPWV
increased by 0.54 m/s ([95% CI: 0.35 to 0.73 m/s]; P0.001)
per quintile unit increase, and after adjustment this was 0.52
m/s ([95% CI: 0.32 to 0.73 m/s]; P0.001).
Discussion
This study investigated the impact of novel and established
cardiovascular risk factors, assessed over 20 years, on current
aortic stiffness and wave reflections, in a cohort of 825 men.
The main novel finding is that, other than BP, traditional
cardiovascular risk factors have only a modest influence on
aPWV and AIx but that CRP is relatively strongly related to
both. Specifically, aPWV was independently associated with
pulse pressure, CRP, glucose, and waist circumference mea-
sured 20 years previously, whereas only fibrinogen indepen-
dently predicted current AIx. Overall, aPWV appeared most
strongly related to cumulative exposure to CRP, baseline
levels of triglycerides, and smoking, but with current waist
circumference. This suggests that some risk factors, for
example, triglycerides, have a long latency period, and
modification in later life may have less to offer in terms of
disease prevention, whereas inflammation shows a persistent
effect, although this may reflect reverse causation rather than
primary etiologic significance. Interestingly, as hypothesized,
Table 2. Associations of Adjusted aPWV and AIx With Factors Assessed at Baseline and Follow-Up
Variable
aPWV AIx
-Coefficient 95% CI Significance -Coefficient 95% CI Significance
Baseline measures, phase I/II
Peripheral systolic BP, mm Hg 0.43 0.23 to 0.64 0.001 0.19 0.32 to 0.70 0.5
Peripheral diastolic BP, mm Hg 0.09 0.12 to 0.30 0.38 0.29 0.28 to 0.86 0.32
Mean pressure, mm Hg 0.27 0.07 to 0.48 0.008 0.04 0.46 to 0.54 0.9
Pulse pressure, mm Hg 0.48 0.28 to 0.68 0.001 0.36 0.17 to 0.89 0.2
Heart rate, bpm 0.33 0.13 to 0.53 0.001 0.13 0.44 to 0.69 0.7
Fibrinogen, g/L 0.32 0.13 to 0.52 0.001 1.02 0.48 to 1.55 0.001
CRP, mg/L 0.50 0.29 to 0.71 0.001 0.64 0.04 to 1.23 0.03
Cholesterol, mmol/L 0.01 0.19 to 0.17 0.93 0.15 0.34 to 0.64 0.5
Triglycerides, mmol/L 0.30 0.12 to 0.49 0.001 0.06 0.44 to 0.56 0.8
Glucose, mmol/L 0.17 0.01 to 0.35 0.06 0.26 0.75 to 0.24 0.3
Creatinine, mol/L 0.23 0.41 to0.05 0.01 0.04 0.47 to 0.55 0.88
Waist circumference, cm 0.21 0.01 to 0.40 0.03 0.22 0.77 to 0.32 0.4
Heavy smoker (15/d) vs other 0.68 0.12 to 1.23 0.02 1.95 0.40 to 3.50 0.01
Follow-up measures, phase V
CRP, mg/L 0.38 0.21 to 0.56 0.001 0.67 0.9 to 1.15 0.006
Cholesterol, mmol/L 0.00 0.18 to 0.18 0.96 0.50 0.02 to 0.97 0.04
Triglycerides, mmol/L 0.17 0.0 to 0.35 0.05 0.11 9.38 to 0.59 0.7
Creatinine, mol/L 0.25 0.07 to 0.43 0.007 0.25 0.73 to 0.22 0.3
Waist circumference, cm 0.25 0.06 to 0.44 0.009 0.49 1.0 to 0.0 0.05
Heavy smoker (15/d) vs other 0.13 0.33 to 0.58 0.6 1.10 0.29 to 2.43 0.10
All of the analyses are adjusted for age, MAP, heart rate, and drug use. Continuous variables were standardized (z score) after
previous transformation if appropriate. -Coefficients represent the change in dependent variable (meters per second for aPWV or
percentage for AIx) for a 1-SD change in the exposure variable.
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the heart rate pulse pressure product over a 20-year period
was significantly correlated with current aPWV, indicating
that aortic stiffness is dependent on cycle number and the
level of cyclic stress.
A number of potential risk factors for arterial stiffening
have been identified, from cross-sectional studies, including
aging,9,10 hypercholesterolemia,25 diabetes,26 cigarette smok-
ing,27,28 CRP,29 and the metabolic syndrome.30,31 However,
previous observations regarding longitudinal changes in
aPWV are limited.13,14 Hypertension, high heart rate, raised
creatinine, and the metabolic syndrome were all associated
with accelerated arterial stiffening. However, follow-up was
only 6 years, the sample size was modest, and data concern-
ing wave reflection, an important predictor of outcome,32,33
were not available. While awaiting further longitudinal data,
an alternative approach is to make use of existing prospective
studies, which have only assessed aPWV and AIx recently,
and examine predictors of stiffness and wave reflection using
historical and concomitant cross-sectional data. Although this
approach does not take into account initial differences in
stiffness (because the data were not collected), it has the
advantage that long-term follow-up is often available and is
likely to provide earlier insights into the pathophysiology of
stiffening.
We conducted an initial cross-sectional analysis between
stiffness measures and factors assessed concomitantly. We
confirmed previous observations that aPWV was signifi-
cantly and positively correlated with MAP, heart rate, CRP,
creatinine, and waist circumference. aPWV was not associ-
ated with any lipid parameters or smoking. Although some
studies have reported an inverse relationship between high-
density lipoprotein cholesterol34 and a positive relationship
with total/low-density lipoprotein cholesterol,35 others have
not.36,37 The present study is among the largest reported25 and
supports the findings of a recent systematic review that the
impact of traditional risk factors, other than BP, on aPWV is
very modest.11 Surprisingly creatinine at baseline was in-
versely associated with aPWV, in contrast with previous
findings,13 although at follow-up it showed the expected
positive association, which may be a type I error. Wave
reflection was significantly associated with current heart rate,
MAP, height, CRP, and total cholesterol, as expected.10,38,39
We then examined the relationship between aortic stiffness
and variables assessed 20 years previously. After adjustment
for concomitant confounders, including age, MAP, heart rate,
and drug use, only pulse pressure, CRP, glucose, and waist
circumference were independent predictors of aPWV. Exam-
ining the strength of association between pairs of variables
measured at baseline and follow-up indicated that, for CRP,
both were strongly related to current aPWV, suggesting that
the long-term inflammation may play a role in aortic stiffen-
ing. Indeed, data indicate that CRP predicts the development
of hypertension,40,41 which may, in part, be a consequence of
arterial stiffening. However, we and others have shown that
functional polymorphisms in the CRP gene do not predict
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Figure 2. Independent predictors of aPWV and AIx
from 20 years before. Data show the results of the
multivariable model of predictors of current aPWV
and AIx using baseline data from 20 years ago
(only significant parameters are shown). Standard-
ized coefficients represent the change in depen-
dent variable (meters per second for aPWV or per-
centage for AIx) for a 1-SD change in the exposure
variable.
Table 3. Multivariable Models for Current aPWV and AIx,
Using Baseline Data (Phase I/II)
Model -Coefficient 95% CI Significance
aPWV (adjusted R 20.35;
P0.001; n592)*
Pulse pressure, mm Hg 0.58 0.33 to 0.84 0.001
Fibrinogen, g/L 0.07 0.16 to 0.30 0.53
CRP, mg/L 0.35 0.12 to 0.57 0.002
Triglycerides, mmol/L 0.20 0.0 to 0.40 0.05
Glucose, mmol/L 0.25 0.04 to 0.45 0.02
Waist circumference, cm 0.23 0.01 to 0.44 0.04
Heavy smoker (15/d)
vs other groups
0.38 0.11 to 0.88 0.13
Aortic AIx (adjusted R 20.31;
P0.001; n572)†
Cholesterol, mmol/L 0.19 0.41 to 0.79 0.54
CRP, mg/L 0.29 0.39 to 0.96 0.41
Fibrinogen, g/L 0.78 0.08 to 1.47 0.03
Waist circumference, cm 0.16 0.80 to 0.47 0.62
Heavy smoker (15/d) vs
other groups
1.19 0.29 to 2.67 0.12
Continuous variables were standardized (z score) after previous transforma-
tion if appropriate. -Coefficients represent the change in dependent variable
(meters per second for aPWV or percentage for AIx) for a 1-SD change in the
exposure variable.
*Data were adjusted for current age, MAP, heart rate, and drug use.
†Data were adjusted for current age, heart rate, height, and drug use.
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aPWV,42 suggesting that CRP itself is not causal but may
reflect inflammatory burden, but “reverse causality” cannot
be excluded. In contrast, aPWV was most strongly associated
with current waist circumference. This may represent simple
confounding, because carotid-femoral path length is more
likely to be overestimated in obese individuals. Although
animal data suggest that this is not the case,43 data in humans
are required.
Only baseline values of fibrinogen, CRP, and smoking
were independently associated with current AIx, and in
multivariable models only fibrinogen remained a weak pre-
dictor, with a very modest effect size. In paired comparisons,
the current values for each of these factors were more
strongly correlated with AIx than baseline data, suggesting
that inflammation and smoking have a relatively short-term
influence on wave reflection. This fits with the notion that
AIx is a more dynamic factor than aPWV, depending on
vascular tone in the small arteries,1,44 rather than on long-term
structural alterations. Moreover, the disparity between factors
linked to aPWV and AIx reinforces the concept that they are
not interchangeable and provide different but complementary
information.3
Fatigue fracture of the elastic elements is often considered
to be responsible for the age-related increase in aPWV.6 The
rate of elastin fracture depends on the number of stress cycles
and level of stress,45 that is, the number of heartbeats and
pulse pressure. Our data demonstrate a significant, indepen-
dent relationship between the heart rate pulse pressure prod-
uct, assessed over 20 years, and aPWV. These effects appear
to be additive and are only minimally attenuated by potential
confounders. This supports O’Rourke’s original hypothesis6
and may provide an explanation for the cross-sectional
association between high heart rate and aPWV,10,46 as well as
epidemiological observations that high heart rate is associated
with increased cardiovascular risk.47 However, because pulse
pressure is, in part, determined by wall stiffness, it will be
important to replicate these observations in cohorts with
baseline aPWV. Nevertheless, our data suggest that arterial
stiffening may be reduced by lowering heart rate and/or pulse
pressure, although this remains to be tested.
Limitations
Because we did not have baseline measures of arterial
stiffness, we could not relate risk factors to changes in arterial
stiffness, that is, stiffening. We did not assess the effect of
metabolic syndrome, per se, on stiffness, rather investigating
the independent predictive value of the individual compo-
nents of the syndrome using multivariable models, because
recent data suggest that the metabolic syndrome is not itself
independently predictive of events.48 We could only assess
men who were available for rescreening. The missing men
had a worse cardiovascular risk profile, suggesting that there
was an element of a “healthy survivor effect.” As such, it is
likely that we may have underestimated the strength of the
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Figure 3. Integrated heart rate and pulse pressure tertiles
across 20 years and their association with aPWV in later life.
Subjects are grouped into tertiles of pulse pressure and heart
rate on the basis of integrated values over the average 20-year
follow-up period. The highest values of velocity are observed in
those in the highest tertiles of pulse pressure and heart rate. P
values for linear effects were 0.001 for each of the 6 strata.
Table 4. Association Between Pairs of Variables Measured at Phases I/II and V and Current aPWV and AIx
Variable
aPWV* AIx†
-Coefficient 95% CI Significance -Coefficient 95% CI Significance
CRP, baseline 0.43 0.20 to 0.66 0.001 0.30 0.34 to 0.95 0.4
CRP, follow-up 0.32 0.12 to 0.51 0.001 0.53 0.0 to 1.06 0.05
Cholesterol, baseline 0.01 0.18 to 2.12 0.9 0.14 0.40 to 0.69 0.6
Cholesterol, follow-up 0.01 0.19 to 0.18 0.9 0.46 0.03 to 0.95 0.07
Triglycerides, baseline 0.25 0.04 to 0.46 0.01 0.15 0.43 to 0.72 0.6
Triglycerides, follow-up 0.07 0.12 to 0.26 0.4 0.09 0.44 to 0.62 0.7
Waist circumference, baseline 0.04 0.35 to 0.28 0.8 0.26 0.60 to 1.13 0.5
Waist circumference, follow-up 0.29 0.01 to 0.59 0.06 0.61 1.43 to 0.22 0.1
Heavy smoker, baseline 0.35 0.03 to 0.73 0.07 0.89 0.23 to 2.02 0.12
Heavy smoker, follow-up 0.09 0.60 to 0.42 0.7 0.58 0.91 to 2.06 0.4
Paired variables are mutually adjusted for each other. -Coefficients represent the change in dependent variable (meters per
second for aPWV or percentage for AIx) for a 1-SD change in the exposure variable.
*Data were adjusted for age, MAP, heart rate, and drug use.
†Data were adjusted for age, heart rate, height, and drug use.
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risk factors for aPWV and AIx. Finally, we cannot comment
on the relevance of our observations to women.
Perspectives
Our data indicate that inflammation and the level of repetitive
cyclic stress are important predictors of aortic stiffening.
Conversely, wave reflection appears to be a much more
dynamic variable and influenced in the short term by inflam-
mation and cigarette smoking. Traditional cardiovascular risk
factors have more modest, or no, effect on aortic stiffness and
wave reflection. Adequate control of pulse pressure and heart
rate may, in the long term, retard aortic stiffening.
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